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Abstract
Purpose The role of tracheostomy in COVID-19-related ARDS is unknown. Nowadays, there is no clear indication regard-
ing the timing of tracheostomy in these patients.
Methods We describe our synergic experience between ENT and ICU Departments at University Hospital of Modena 
underlining some controversial aspects that would be worth discussing tracheostomies in these patients. During the last 
2 weeks, we performed 28 tracheostomies on patients with ARDS due to COVID-19 infection who were treated with IMV.
Results No differences between percutaneous and surgical tracheostomy in terms of timing and no case of team virus 
infection.
Conclusion In our experience, tracheostomy should be performed only in selected patients within 7- and 14-day orotracheal 
intubation.
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To date, over 940,000 “Coronavirus Disease 2019” (COVID-
19) cases have been confirmed, with over 39,000 deaths. At 
the writing time, the COVID-19 epidemic is striking hard 
in Italy, being the second country in terms of infected and 
dead people. The mortality appears to be around 2%; early 
published data indicate 25.9% with COVID-19 pneumonia 
required intensive care unit (ICU) admission and 20.1% 
developed acute respiratory distress syndrome (ARDS) [1, 
2]. Non-invasive support methods (i.e., CPAP, BiPAP, NIV, 
HFNO) might correct hypoxemia and avoid endotracheal 
intubation but may either delay intubation with potential 
complications. Invasive mechanical ventilation (IMV) via 
an endotracheal tube (ETT) is being commonly employed 
during this outbreak.
Tracheostomy is a widely used intervention in patients 
with acute respiratory failure, especially when clinicians pre-
dict a patient’s need for prolonged IMV, but at the moment, 
no recommendation on COVID-19-affected patients exists 
[3].
Herein, we describe our synergic experience between 
ENT and ICU Departments at University Hospital of Mod-
ena underlining some controversial aspects that would worth 
discussing tracheostomies in these patients.
During the last 2 weeks, we performed 28 tracheostomies 
on patients with ARDS due to COVID-19 infection who 
were treated with IMV.
There are no studies addressing mechanical ventilation 
strategies in COVID-19 outbreaks. COVID-19-related 
ARDS often requires prolonged intubation as observed in 
our experience. In addition, early extubating attempts fre-
quently require a re-intubation procedure. According to 
Meng et al. these should be considered difficult and compli-
cated intubations for different reasons (i.e., no respiratory 
reserve, strict infection control and urgency, personal protec-
tive equipment, psychological pressure) [4].
Tracheostomy offers several advantages in terms of 
improved comfort management, reduced sedative, and 
paralytic medical support, reducing death space. Moreover, 
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tracheostomy reduces airways resistance, lessening the work 
of breathing optimizing the tracheal secretion control [5].
This procedure results in better patient comfort and facili-
tates restoring patient autonomy, even if it carries its own 
risks. Aerosol-generating procedures, such as endotracheal 
intubation, extubation, and tracheostomy, have been impli-
cated with the transmission of infectious agents to healthcare 
personnel in previous papers regarding the SARS outbreak.
An increasing need for ICU admission due to COVID-
19-related ARDS can be expected within the next months. 
The magnitude of this demand may cause an imbalance 
between the real clinical needs of the population and the 
effective availability of intensive resources. This scenario 
can be substantially assimilated to the field of “Disaster 
medicine” where tracheostomy is a tool for early ICU dis-
charge [3]. Indeed, tracheostomy could allow discharge from 
ICU to intermediate care ward in patients with ongoing IMV.
In the LUNG SAFE study, involving ARDS patients from 
459 ICUs across 50 countries, tracheostomy was performed 
in 13% of patients, whose 75% after the first week of ICU 
stay [6]. The median timing of tracheostomy was 14 days 
after the onset of ARDS. The difficulty for clinicians in 
predicting which patients will require prolonged ventilation 
support in the early phases of critical illness is a caveat. 
There is no identified time point when afflicted patients 
either improve, remain stable, or progress toward death due 
to pulmonary complications.
No recommendation can be given about tracheostomy 
within 7 days in COVID-19 patients. In this early phase, 
aggressive treatments and intensive care are needed for 
critically ill patients and tracheostomy could not result in 
improvement in hypoxia, multiple organ dysfunction, virus 
clearance, and in shorter duration of IMV.
If the patient meets weaning targets like FiO2 less than 
40%, PEEP < 8, PaO2/FiO2 > 200, pressure support < 8 
 cmH2O, extubation could be reached between 7 and 14 days, 
tracheostomy should be postponed.
After 7 days in patients far from reaching weaning targets, 
tracheostomy could be performed, but there is a lack of data 
regarding this topic.
Additional critical outcome scores, such as high res-
piratory SOFA score, might be beneficial to identify those 
COVID-19 patients who are too sick to benefit from further 
interventional procedure [7].
Moreover, performing a tracheostomy appears to be 
influenced by other factors as local medical practices and 
expertise and costs relating to the procedure and equipment.
In our experience, several delayed (> 14 OTI days) tra-
cheostomies were performed especially in the first-affected 
intubated cases who required re-intubation without clini-
cal improvement, and in case of lack of ICU places. We 
report a case where important tracheomalacia and poste-
rior tracheal wall damage were observed after the opening 
of the trachea, probably caused by prolonged over-cuffed 
intubation and/or prone position ventilation or previously 
repeated extubation and re-intubation procedures. We did 
not delay tracheostomy timing until the COVID-19 de-
activation time was reached and no one has been infected. 
However, unless emergent, surgical procedures should 
only be undertaken after ascertaining the COVID-19 status 
to decrease potential virus exposure to the team.
It is recommended during aerosol-generating proce-
dures on patients with COVID-19 to wear a fit-tested N95 
mask in addition to gloves, gown, face/eye protection 
and to perform these procedures in an airborne isolation 
room. Both percutaneous and surgical tracheostomies can 
be performed. Surgical tracheostomy should be indicated 
for BMI > 30 patients with short neck and documented 
thyroid gland hypertrophy. We have been always per-
forming trans-isthmus tracheostomy with tracheal-to-
skin stitches on inferior margin without ETT removal to 
avoid accidental displacement of tracheal cannula. Cuffed 
non-fenestrated cannula should be used to limit diffusion 
of the virus. Every effort should be made not to pierce 
the cuff of the ETT when performing tracheostomy. Ini-
tial advancement of the ETT should be performed prior 
to tracheostomy window being made. Ventilation has to 
cease prior to tracheostomy tube insertion, which has to be 
swift and accurate with prompt inflation of the cuff. Most 
skilled ENT surgeon should perform the procedure due to 
the uncomfortable setting of the ICU COVID-19 room and 
personal protective equipment.
The role of tracheostomy in COVID-19-related ARDS 
is unknown. Nowadays, there is no clear indication regard-
ing the timing of tracheostomy in these patients. There is 
no evidence that tracheostomy improves patient’s clinical 
course. It is established that tracheostomy reduces the ICU 
stay. In the context of prolonged IMV required in COVID-
19 experience, tracheostomy should be suggested to avoid 
potential tracheal damages within 7 and 14 days. Surgical 
tracheostomy should be proposed only in selected patients.
The ENT and ICU specialists should pay meticulous 
attention to the details of infection control, to minimize 
cross-contamination and their own risk of contracting the 
illness. We suggest other colleagues to share their experi-
ence with this topic.
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